Medical News Today: What are the side effects and risks of Ritalin?
Ritalin (methylphenidate) is a stimulant medication for the treatment of ADHD and narcolepsy. Ritalin can cause side effects and has the potential for misuse and addiction. Researchers are investigating the long-term safety and effectiveness of this drug in children and adolescents. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
The association between attention-deficit hyperactivity disorder, injuries, and methylphenidate - Shem-Tov S, Chodick G, Weitzman D, Koren G.
Objective. To evaluate the relationship between attention-deficit hyperactivity disorder (ADHD) and injuries and to verify whether methylphenidate (MPH), is associated with decreasing the risk of injuries.
Methods. A retrospective cohort ... (Source: SafetyLit)
Source: SafetyLit - May 26, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Methylphenidate Capsules for Morning ADHD Symptom Control Methylphenidate Capsules for Morning ADHD Symptom Control
Newly approved delayed- and extended-release methylphenidate capsules designed for bedtime administration may provide better early morning symptom control for ADHD patients.Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2019 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
Amid America's opioid crisis, deaths from stimulants are steadily rising
Overdose deaths involving cocaine and psychotstimulants such as methamphematines, MDMA, methylphenidate (commonly sold as Ritalin) and caffeine have been steadily rising, according to a new report from the US Centers for Disease Control and Prevention. (Source: CNN.com - Health)
Source: CNN.com - Health - May 2, 2019 Category: Consumer Health News Source Type: news
Lannett To Launch Generic Concerta(R), AB-rated Methylphenidate Hydrochloride ER Tablets
PHILADELPHIA, April 30, 2019 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg,... Biopharmaceuticals, Generics, Product Launch Lannett, Concerta , Methylphenidate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves First Medical Device To Treat ADHD In Children
(CNN) — The first medical device to treat childhood attention deficit hyperactivity disorder, or ADHD, was OK’d Friday by the US Food and Drug Administration. Designated for children ages 7 to 12 who are not currently on medication for the disorder, the device delivers a low-level electrical pulse to the parts of the brain responsible for ADHD symptoms.
“This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,” Carlos Peña, director of the Division of Neurological and Physical Medicine Devices in the F...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 22, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN ADHD Source Type: news
Can delayed/extended-release methylphenidate allow for once daily evening dosing in ADHD?
(Mary Ann Liebert, Inc./Genetic Engineering News) A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2019 Category: International Medicine & Public Health Source Type: news
ANI Pharmaceuticals Announces Two Generic Product Launches
BAUDETTE, Minn., March 27, 2019 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release T... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Methylphenidate, Attention Deficit Hyperactivity Disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2019 Category: Pharmaceuticals Source Type: news
Childhood methylphenidate treatment predicts antidepressant use during adolescence
(Bar-Ilan University) A new, 12-year longitudinal study, which monitored 6,830 children from early childhood into adolescence, has shown that consistent treatment with MPH-based medications during childhood increases the risk of antidepressant use during adolescence. The study is the first of its kind to examine the connection between children diagnosed with ADHD and prescribed MPH between the ages of six and eight, and future dispensed prescriptions of antidepressants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 27, 2019 Category: International Medicine & Public Health Source Type: news
In Youth With ADHD, New-Onset Psychosis Up With Amphetamines
THURSDAY, March 21, 2019 -- For adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD), new-onset psychosis occurs more often with amphetamine use versus methylphenidate use, according to a study published in the March 21... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2019 Category: Pharmaceuticals Source Type: news
Some ADHD Meds Tied to a Higher Psychosis Risk Than Others Some ADHD Meds Tied to a Higher Psychosis Risk Than Others
Amphetamines are associated with a higher psychosis risk than methylphenidate in young patients who take these agents to treat attention deficit hyperactivity disorder.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 20, 2019 Category: Primary Care Tags: Psychiatry News Source Type: news
With ADHD, amphetamine has double the psychosis risk of methylphenidate
(Reuters Health) - Children and young adults with attention deficit-hyperactivity disorder (ADHD) who are treated with the stimulants amphetamine or methylphenidate face a small but significant risk of developing psychosis, with amphetamine products twice as likely to spark at problem, researchers say. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Popular Spice Rivals Stimulant for ADHD Popular Spice Rivals Stimulant for ADHD
The popular and expensive spice saffron appears to be as effective as the stimulant methylphenidate in treating symptoms in youngsters with ADHD, new research suggests.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news
Adhansia XR (Methylphenidate Hydrochloride Extended-release Capsules) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2019 Category: Drugs & Pharmacology Source Type: news
